Lonza Group AG
Lonza Group AG (LZAGF) Stock Competitors & Peer Comparison
See (LZAGF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LZAGF | $629.71 | -3.33% | 43.2B | 37.47 | $16.51 | +0.49% |
| WUXAY | $15.94 | -1.06% | 45.9B | 15.63 | $1.02 | +1.76% |
| LZAGY | $63.23 | +0.67% | 44.9B | 38.26 | $1.65 | +0.90% |
| WUXIF | $13.88 | +0.00% | 41.4B | 13.74 | $1.01 | +2.03% |
| ERFSF | $74.05 | +2.23% | 13.1B | 25.28 | $2.97 | +1.16% |
| BMXMF | $87.42 | +0.00% | 10.3B | 22.47 | $3.89 | +1.18% |
| BMXXY | $7.91 | -4.73% | 9.3B | 20.28 | $0.39 | +1.31% |
| SKHHY | $13.47 | -1.05% | 6.7B | 17.04 | $0.79 | +5.45% |
| HNGZY | $4.00 | +0.00% | 6.2B | 26.67 | $0.15 | +0.72% |
| SKHCF | $12.00 | +0.00% | 5.9B | 15.19 | $0.79 | +6.05% |
Stock Comparison
LZAGF vs WUXAY Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, WUXAY has a market cap of 45.9B. Regarding current trading prices, LZAGF is priced at $629.71, while WUXAY trades at $15.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas WUXAY's P/E ratio is 15.63. In terms of profitability, LZAGF's ROE is +0.10%, compared to WUXAY's ROE of +0.27%. Regarding short-term risk, LZAGF is more volatile compared to WUXAY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check WUXAY's competition here
LZAGF vs LZAGY Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, LZAGY has a market cap of 44.9B. Regarding current trading prices, LZAGF is priced at $629.71, while LZAGY trades at $63.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas LZAGY's P/E ratio is 38.26. In terms of profitability, LZAGF's ROE is +0.10%, compared to LZAGY's ROE of +0.10%. Regarding short-term risk, LZAGF is more volatile compared to LZAGY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check LZAGY's competition here
LZAGF vs WUXIF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, WUXIF has a market cap of 41.4B. Regarding current trading prices, LZAGF is priced at $629.71, while WUXIF trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas WUXIF's P/E ratio is 13.74. In terms of profitability, LZAGF's ROE is +0.10%, compared to WUXIF's ROE of +0.27%. Regarding short-term risk, LZAGF is more volatile compared to WUXIF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check WUXIF's competition here
LZAGF vs ERFSF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, ERFSF has a market cap of 13.1B. Regarding current trading prices, LZAGF is priced at $629.71, while ERFSF trades at $74.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas ERFSF's P/E ratio is 25.28. In terms of profitability, LZAGF's ROE is +0.10%, compared to ERFSF's ROE of +0.12%. Regarding short-term risk, LZAGF is less volatile compared to ERFSF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check ERFSF's competition here
LZAGF vs BMXMF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, BMXMF has a market cap of 10.3B. Regarding current trading prices, LZAGF is priced at $629.71, while BMXMF trades at $87.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas BMXMF's P/E ratio is 22.47. In terms of profitability, LZAGF's ROE is +0.10%, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, LZAGF is less volatile compared to BMXMF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check BMXMF's competition here
LZAGF vs BMXXY Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, BMXXY has a market cap of 9.3B. Regarding current trading prices, LZAGF is priced at $629.71, while BMXXY trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas BMXXY's P/E ratio is 20.28. In terms of profitability, LZAGF's ROE is +0.10%, compared to BMXXY's ROE of +0.10%. Regarding short-term risk, LZAGF is more volatile compared to BMXXY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BMXXY's competition here
LZAGF vs SKHHY Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, SKHHY has a market cap of 6.7B. Regarding current trading prices, LZAGF is priced at $629.71, while SKHHY trades at $13.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas SKHHY's P/E ratio is 17.04. In terms of profitability, LZAGF's ROE is +0.10%, compared to SKHHY's ROE of +0.05%. Regarding short-term risk, LZAGF is less volatile compared to SKHHY. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check SKHHY's competition here
LZAGF vs HNGZY Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, HNGZY has a market cap of 6.2B. Regarding current trading prices, LZAGF is priced at $629.71, while HNGZY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, LZAGF's ROE is +0.10%, compared to HNGZY's ROE of +0.04%. Regarding short-term risk, LZAGF is more volatile compared to HNGZY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check HNGZY's competition here
LZAGF vs SKHCF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, SKHCF has a market cap of 5.9B. Regarding current trading prices, LZAGF is priced at $629.71, while SKHCF trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas SKHCF's P/E ratio is 15.19. In terms of profitability, LZAGF's ROE is +0.10%, compared to SKHCF's ROE of +0.06%. Regarding short-term risk, LZAGF is less volatile compared to SKHCF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check SKHCF's competition here
LZAGF vs DSRLF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, DSRLF has a market cap of 3.9B. Regarding current trading prices, LZAGF is priced at $629.71, while DSRLF trades at $73.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas DSRLF's P/E ratio is 24.13. In terms of profitability, LZAGF's ROE is +0.10%, compared to DSRLF's ROE of +0.12%. Regarding short-term risk, LZAGF is more volatile compared to DSRLF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check DSRLF's competition here
LZAGF vs TCGGY Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, TCGGY has a market cap of 2.3B. Regarding current trading prices, LZAGF is priced at $629.71, while TCGGY trades at $36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas TCGGY's P/E ratio is 27.27. In terms of profitability, LZAGF's ROE is +0.10%, compared to TCGGY's ROE of -0.09%. Regarding short-term risk, LZAGF is more volatile compared to TCGGY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check TCGGY's competition here
LZAGF vs TCHBF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, TCHBF has a market cap of 2.2B. Regarding current trading prices, LZAGF is priced at $629.71, while TCHBF trades at $177.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas TCHBF's P/E ratio is -15.95. In terms of profitability, LZAGF's ROE is +0.10%, compared to TCHBF's ROE of -0.09%. Regarding short-term risk, LZAGF is more volatile compared to TCHBF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check TCHBF's competition here
LZAGF vs STSEY Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, STSEY has a market cap of 1.7B. Regarding current trading prices, LZAGF is priced at $629.71, while STSEY trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas STSEY's P/E ratio is -78.71. In terms of profitability, LZAGF's ROE is +0.10%, compared to STSEY's ROE of -0.01%. Regarding short-term risk, LZAGF is more volatile compared to STSEY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check STSEY's competition here
LZAGF vs VIMGF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, VIMGF has a market cap of 1.5B. Regarding current trading prices, LZAGF is priced at $629.71, while VIMGF trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas VIMGF's P/E ratio is 39.57. In terms of profitability, LZAGF's ROE is +0.10%, compared to VIMGF's ROE of +0.05%. Regarding short-term risk, LZAGF is more volatile compared to VIMGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check VIMGF's competition here
LZAGF vs GNTLF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, GNTLF has a market cap of 1.3B. Regarding current trading prices, LZAGF is priced at $629.71, while GNTLF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, LZAGF's ROE is +0.10%, compared to GNTLF's ROE of -1.85%. Regarding short-term risk, LZAGF is more volatile compared to GNTLF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check GNTLF's competition here
LZAGF vs MRCHF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, MRCHF has a market cap of 1.1B. Regarding current trading prices, LZAGF is priced at $629.71, while MRCHF trades at $19.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas MRCHF's P/E ratio is 25.67. In terms of profitability, LZAGF's ROE is +0.10%, compared to MRCHF's ROE of +0.05%. Regarding short-term risk, LZAGF is more volatile compared to MRCHF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check MRCHF's competition here
LZAGF vs IDGXF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, IDGXF has a market cap of 345.7M. Regarding current trading prices, LZAGF is priced at $629.71, while IDGXF trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas IDGXF's P/E ratio is 11.89. In terms of profitability, LZAGF's ROE is +0.10%, compared to IDGXF's ROE of +0.42%. Regarding short-term risk, LZAGF is more volatile compared to IDGXF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check IDGXF's competition here
LZAGF vs EDTXF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, EDTXF has a market cap of 296.4M. Regarding current trading prices, LZAGF is priced at $629.71, while EDTXF trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas EDTXF's P/E ratio is -11.22. In terms of profitability, LZAGF's ROE is +0.10%, compared to EDTXF's ROE of +0.61%. Regarding short-term risk, LZAGF is more volatile compared to EDTXF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check EDTXF's competition here
LZAGF vs PFGTF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, PFGTF has a market cap of 197.6M. Regarding current trading prices, LZAGF is priced at $629.71, while PFGTF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas PFGTF's P/E ratio is -9.66. In terms of profitability, LZAGF's ROE is +0.10%, compared to PFGTF's ROE of -1.91%. Regarding short-term risk, LZAGF is more volatile compared to PFGTF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check PFGTF's competition here
LZAGF vs DIUXF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, DIUXF has a market cap of 173.5M. Regarding current trading prices, LZAGF is priced at $629.71, while DIUXF trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas DIUXF's P/E ratio is -102.50. In terms of profitability, LZAGF's ROE is +0.10%, compared to DIUXF's ROE of -0.04%. Regarding short-term risk, LZAGF is more volatile compared to DIUXF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check DIUXF's competition here
LZAGF vs AMCY Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, AMCY has a market cap of 171.3M. Regarding current trading prices, LZAGF is priced at $629.71, while AMCY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas AMCY's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to AMCY's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to AMCY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check AMCY's competition here
LZAGF vs NNGRF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, NNGRF has a market cap of 164.3M. Regarding current trading prices, LZAGF is priced at $629.71, while NNGRF trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, LZAGF's ROE is +0.10%, compared to NNGRF's ROE of -0.05%. Regarding short-term risk, LZAGF is more volatile compared to NNGRF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check NNGRF's competition here
LZAGF vs CORBF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, CORBF has a market cap of 133.9M. Regarding current trading prices, LZAGF is priced at $629.71, while CORBF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas CORBF's P/E ratio is 2.86. In terms of profitability, LZAGF's ROE is +0.10%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, LZAGF is more volatile compared to CORBF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check CORBF's competition here
LZAGF vs THOXF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, THOXF has a market cap of 73.8M. Regarding current trading prices, LZAGF is priced at $629.71, while THOXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas THOXF's P/E ratio is -7.45. In terms of profitability, LZAGF's ROE is +0.10%, compared to THOXF's ROE of -1.67%. Regarding short-term risk, LZAGF is less volatile compared to THOXF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check THOXF's competition here
LZAGF vs TIHE Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, TIHE has a market cap of 71.9M. Regarding current trading prices, LZAGF is priced at $629.71, while TIHE trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas TIHE's P/E ratio is 0.32. In terms of profitability, LZAGF's ROE is +0.10%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, LZAGF is more volatile compared to TIHE. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check TIHE's competition here
LZAGF vs BIOGF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, BIOGF has a market cap of 65.4M. Regarding current trading prices, LZAGF is priced at $629.71, while BIOGF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, LZAGF's ROE is +0.10%, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, LZAGF is more volatile compared to BIOGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BIOGF's competition here
LZAGF vs LDXHF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, LDXHF has a market cap of 64.9M. Regarding current trading prices, LZAGF is priced at $629.71, while LDXHF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas LDXHF's P/E ratio is -8.50. In terms of profitability, LZAGF's ROE is +0.10%, compared to LDXHF's ROE of -1.21%. Regarding short-term risk, LZAGF is more volatile compared to LDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check LDXHF's competition here
LZAGF vs PCNEF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, PCNEF has a market cap of 62M. Regarding current trading prices, LZAGF is priced at $629.71, while PCNEF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, LZAGF's ROE is +0.10%, compared to PCNEF's ROE of -0.05%. Regarding short-term risk, LZAGF is less volatile compared to PCNEF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check PCNEF's competition here
LZAGF vs BMKDF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, BMKDF has a market cap of 53M. Regarding current trading prices, LZAGF is priced at $629.71, while BMKDF trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas BMKDF's P/E ratio is -50.44. In terms of profitability, LZAGF's ROE is +0.10%, compared to BMKDF's ROE of -1.53%. Regarding short-term risk, LZAGF is more volatile compared to BMKDF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BMKDF's competition here
LZAGF vs BIOQ Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, BIOQ has a market cap of 31.3M. Regarding current trading prices, LZAGF is priced at $629.71, while BIOQ trades at $35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas BIOQ's P/E ratio is 15.84. In terms of profitability, LZAGF's ROE is +0.10%, compared to BIOQ's ROE of -0.03%. Regarding short-term risk, LZAGF is more volatile compared to BIOQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BIOQ's competition here
LZAGF vs ABDXF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, ABDXF has a market cap of 30.3M. Regarding current trading prices, LZAGF is priced at $629.71, while ABDXF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas ABDXF's P/E ratio is -16.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to ABDXF's ROE of -0.45%. Regarding short-term risk, LZAGF is more volatile compared to ABDXF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check ABDXF's competition here
LZAGF vs LDDD Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, LDDD has a market cap of 28M. Regarding current trading prices, LZAGF is priced at $629.71, while LDDD trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas LDDD's P/E ratio is -93.40. In terms of profitability, LZAGF's ROE is +0.10%, compared to LDDD's ROE of -0.36%. Regarding short-term risk, LZAGF is more volatile compared to LDDD. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check LDDD's competition here
LZAGF vs SNANF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, SNANF has a market cap of 25.6M. Regarding current trading prices, LZAGF is priced at $629.71, while SNANF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas SNANF's P/E ratio is -11.19. In terms of profitability, LZAGF's ROE is +0.10%, compared to SNANF's ROE of -10.44%. Regarding short-term risk, LZAGF is more volatile compared to SNANF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check SNANF's competition here
LZAGF vs CLIFF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, CLIFF has a market cap of 23.1M. Regarding current trading prices, LZAGF is priced at $629.71, while CLIFF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas CLIFF's P/E ratio is -2.25. In terms of profitability, LZAGF's ROE is +0.10%, compared to CLIFF's ROE of -0.11%. Regarding short-term risk, LZAGF is more volatile compared to CLIFF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check CLIFF's competition here
LZAGF vs ANPCY Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, ANPCY has a market cap of 22M. Regarding current trading prices, LZAGF is priced at $629.71, while ANPCY trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas ANPCY's P/E ratio is -0.10. In terms of profitability, LZAGF's ROE is +0.10%, compared to ANPCY's ROE of -0.90%. Regarding short-term risk, LZAGF is more volatile compared to ANPCY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check ANPCY's competition here
LZAGF vs PCHM Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, PCHM has a market cap of 22M. Regarding current trading prices, LZAGF is priced at $629.71, while PCHM trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas PCHM's P/E ratio is -0.02. In terms of profitability, LZAGF's ROE is +0.10%, compared to PCHM's ROE of +0.25%. Regarding short-term risk, LZAGF is more volatile compared to PCHM. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check PCHM's competition here
LZAGF vs VILGF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, VILGF has a market cap of 20.7M. Regarding current trading prices, LZAGF is priced at $629.71, while VILGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas VILGF's P/E ratio is -0.30. In terms of profitability, LZAGF's ROE is +0.10%, compared to VILGF's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to VILGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check VILGF's competition here
LZAGF vs JMPHF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, JMPHF has a market cap of 15.2M. Regarding current trading prices, LZAGF is priced at $629.71, while JMPHF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas JMPHF's P/E ratio is 8.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to JMPHF's ROE of +0.31%. Regarding short-term risk, LZAGF is more volatile compared to JMPHF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check JMPHF's competition here
LZAGF vs IZOZF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, IZOZF has a market cap of 10.4M. Regarding current trading prices, LZAGF is priced at $629.71, while IZOZF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas IZOZF's P/E ratio is -7.50. In terms of profitability, LZAGF's ROE is +0.10%, compared to IZOZF's ROE of +0.48%. Regarding short-term risk, LZAGF is less volatile compared to IZOZF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check IZOZF's competition here
LZAGF vs MXDHF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, MXDHF has a market cap of 8.6M. Regarding current trading prices, LZAGF is priced at $629.71, while MXDHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, LZAGF's ROE is +0.10%, compared to MXDHF's ROE of +4.03%. Regarding short-term risk, LZAGF is more volatile compared to MXDHF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check MXDHF's competition here
LZAGF vs IDXG Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, IDXG has a market cap of 8M. Regarding current trading prices, LZAGF is priced at $629.71, while IDXG trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas IDXG's P/E ratio is 2.07. In terms of profitability, LZAGF's ROE is +0.10%, compared to IDXG's ROE of +2.15%. Regarding short-term risk, LZAGF is more volatile compared to IDXG. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check IDXG's competition here
LZAGF vs ANPCF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, ANPCF has a market cap of 6.5M. Regarding current trading prices, LZAGF is priced at $629.71, while ANPCF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas ANPCF's P/E ratio is -0.33. In terms of profitability, LZAGF's ROE is +0.10%, compared to ANPCF's ROE of -0.90%. Regarding short-term risk, LZAGF is more volatile compared to ANPCF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check ANPCF's competition here
LZAGF vs IMMVF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, IMMVF has a market cap of 6.1M. Regarding current trading prices, LZAGF is priced at $629.71, while IMMVF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas IMMVF's P/E ratio is -0.50. In terms of profitability, LZAGF's ROE is +0.10%, compared to IMMVF's ROE of -3.53%. Regarding short-term risk, LZAGF is more volatile compared to IMMVF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check IMMVF's competition here
LZAGF vs SQIDF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, SQIDF has a market cap of 6.1M. Regarding current trading prices, LZAGF is priced at $629.71, while SQIDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, LZAGF's ROE is +0.10%, compared to SQIDF's ROE of +4.47%. Regarding short-term risk, LZAGF is less volatile compared to SQIDF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check SQIDF's competition here
LZAGF vs PMSNF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, PMSNF has a market cap of 5.8M. Regarding current trading prices, LZAGF is priced at $629.71, while PMSNF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas PMSNF's P/E ratio is -1.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to PMSNF's ROE of +0.34%. Regarding short-term risk, LZAGF is more volatile compared to PMSNF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check PMSNF's competition here
LZAGF vs AVCRF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, AVCRF has a market cap of 4.8M. Regarding current trading prices, LZAGF is priced at $629.71, while AVCRF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas AVCRF's P/E ratio is -4.70. In terms of profitability, LZAGF's ROE is +0.10%, compared to AVCRF's ROE of -1.41%. Regarding short-term risk, LZAGF is more volatile compared to AVCRF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check AVCRF's competition here
LZAGF vs VRCDF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, VRCDF has a market cap of 4.5M. Regarding current trading prices, LZAGF is priced at $629.71, while VRCDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas VRCDF's P/E ratio is -0.10. In terms of profitability, LZAGF's ROE is +0.10%, compared to VRCDF's ROE of -1.93%. Regarding short-term risk, LZAGF is more volatile compared to VRCDF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check VRCDF's competition here
LZAGF vs RNVA Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, RNVA has a market cap of 4.3M. Regarding current trading prices, LZAGF is priced at $629.71, while RNVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas RNVA's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, LZAGF is more volatile compared to RNVA. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check RNVA's competition here
LZAGF vs TDSGF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, TDSGF has a market cap of 4M. Regarding current trading prices, LZAGF is priced at $629.71, while TDSGF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas TDSGF's P/E ratio is -4.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to TDSGF's ROE of -9.19%. Regarding short-term risk, LZAGF is less volatile compared to TDSGF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check TDSGF's competition here
LZAGF vs ICBU Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, ICBU has a market cap of 3.4M. Regarding current trading prices, LZAGF is priced at $629.71, while ICBU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas ICBU's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to ICBU's ROE of -0.22%. Regarding short-term risk, LZAGF is less volatile compared to ICBU. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check ICBU's competition here
LZAGF vs IBXXF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, IBXXF has a market cap of 2.2M. Regarding current trading prices, LZAGF is priced at $629.71, while IBXXF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas IBXXF's P/E ratio is -1.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to IBXXF's ROE of +1.43%. Regarding short-term risk, LZAGF is more volatile compared to IBXXF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check IBXXF's competition here
LZAGF vs CHHL Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, CHHL has a market cap of 1.8M. Regarding current trading prices, LZAGF is priced at $629.71, while CHHL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas CHHL's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to CHHL's ROE of +0.00%. Regarding short-term risk, LZAGF is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check CHHL's competition here
LZAGF vs SLDX Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, SLDX has a market cap of 1.4M. Regarding current trading prices, LZAGF is priced at $629.71, while SLDX trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas SLDX's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to SLDX's ROE of +0.17%. Regarding short-term risk, LZAGF is less volatile compared to SLDX. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check SLDX's competition here
LZAGF vs IVRO Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, IVRO has a market cap of 1.2M. Regarding current trading prices, LZAGF is priced at $629.71, while IVRO trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas IVRO's P/E ratio is -0.56. In terms of profitability, LZAGF's ROE is +0.10%, compared to IVRO's ROE of +0.06%. Regarding short-term risk, LZAGF is less volatile compared to IVRO. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check IVRO's competition here
LZAGF vs DIGP Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, DIGP has a market cap of 1.1M. Regarding current trading prices, LZAGF is priced at $629.71, while DIGP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas DIGP's P/E ratio is -1.04. In terms of profitability, LZAGF's ROE is +0.10%, compared to DIGP's ROE of +0.96%. Regarding short-term risk, LZAGF is less volatile compared to DIGP. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check DIGP's competition here
LZAGF vs EPGNF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, EPGNF has a market cap of 982.2K. Regarding current trading prices, LZAGF is priced at $629.71, while EPGNF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas EPGNF's P/E ratio is -0.30. In terms of profitability, LZAGF's ROE is +0.10%, compared to EPGNF's ROE of +0.03%. Regarding short-term risk, LZAGF is more volatile compared to EPGNF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check EPGNF's competition here
LZAGF vs RSHN Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, RSHN has a market cap of 857.6K. Regarding current trading prices, LZAGF is priced at $629.71, while RSHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas RSHN's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, LZAGF is less volatile compared to RSHN. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check RSHN's competition here
LZAGF vs IDTA Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, IDTA has a market cap of 716.1K. Regarding current trading prices, LZAGF is priced at $629.71, while IDTA trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas IDTA's P/E ratio is 4.43. In terms of profitability, LZAGF's ROE is +0.10%, compared to IDTA's ROE of +0.22%. Regarding short-term risk, LZAGF is less volatile compared to IDTA. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check IDTA's competition here
LZAGF vs SZLSF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, SZLSF has a market cap of 630K. Regarding current trading prices, LZAGF is priced at $629.71, while SZLSF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas SZLSF's P/E ratio is -0.04. In terms of profitability, LZAGF's ROE is +0.10%, compared to SZLSF's ROE of +4.82%. Regarding short-term risk, LZAGF is more volatile compared to SZLSF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check SZLSF's competition here
LZAGF vs SCRSF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, SCRSF has a market cap of 600.3K. Regarding current trading prices, LZAGF is priced at $629.71, while SCRSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas SCRSF's P/E ratio is -0.20. In terms of profitability, LZAGF's ROE is +0.10%, compared to SCRSF's ROE of +2.02%. Regarding short-term risk, LZAGF is more volatile compared to SCRSF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check SCRSF's competition here
LZAGF vs NSTM Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, NSTM has a market cap of 493.3K. Regarding current trading prices, LZAGF is priced at $629.71, while NSTM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas NSTM's P/E ratio is 0.20. In terms of profitability, LZAGF's ROE is +0.10%, compared to NSTM's ROE of -1.25%. Regarding short-term risk, LZAGF is less volatile compared to NSTM. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check NSTM's competition here
LZAGF vs MBGNF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, MBGNF has a market cap of 101.8K. Regarding current trading prices, LZAGF is priced at $629.71, while MBGNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas MBGNF's P/E ratio is -0.59. In terms of profitability, LZAGF's ROE is +0.10%, compared to MBGNF's ROE of +0.23%. Regarding short-term risk, LZAGF is less volatile compared to MBGNF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check MBGNF's competition here
LZAGF vs NVTAQ Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, NVTAQ has a market cap of 85.9K. Regarding current trading prices, LZAGF is priced at $629.71, while NVTAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to NVTAQ's ROE of +0.00%. Regarding short-term risk, LZAGF is less volatile compared to NVTAQ. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check NVTAQ's competition here
LZAGF vs HCLC Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, HCLC has a market cap of 74K. Regarding current trading prices, LZAGF is priced at $629.71, while HCLC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas HCLC's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to HCLC's ROE of +0.11%. Regarding short-term risk, LZAGF is more volatile compared to HCLC. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check HCLC's competition here
LZAGF vs MEDD Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, MEDD has a market cap of 31.9K. Regarding current trading prices, LZAGF is priced at $629.71, while MEDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas MEDD's P/E ratio is -0.01. In terms of profitability, LZAGF's ROE is +0.10%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, LZAGF is more volatile compared to MEDD. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check MEDD's competition here
LZAGF vs TOMDF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, TOMDF has a market cap of 14.1K. Regarding current trading prices, LZAGF is priced at $629.71, while TOMDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas TOMDF's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, LZAGF is more volatile compared to TOMDF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check TOMDF's competition here
LZAGF vs CGNH Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, CGNH has a market cap of 12K. Regarding current trading prices, LZAGF is priced at $629.71, while CGNH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas CGNH's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, LZAGF is more volatile compared to CGNH. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check CGNH's competition here
LZAGF vs ARYC Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, ARYC has a market cap of 7.9K. Regarding current trading prices, LZAGF is priced at $629.71, while ARYC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas ARYC's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to ARYC's ROE of +0.55%. Regarding short-term risk, LZAGF is less volatile compared to ARYC. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check ARYC's competition here
LZAGF vs ABMC Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, ABMC has a market cap of 4.8K. Regarding current trading prices, LZAGF is priced at $629.71, while ABMC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas ABMC's P/E ratio is 0.01. In terms of profitability, LZAGF's ROE is +0.10%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, LZAGF is more volatile compared to ABMC. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check ABMC's competition here
LZAGF vs CYPS Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, CYPS has a market cap of 4.1K. Regarding current trading prices, LZAGF is priced at $629.71, while CYPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas CYPS's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to CYPS's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to CYPS. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check CYPS's competition here
LZAGF vs RGDXQ Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, RGDXQ has a market cap of 3.9K. Regarding current trading prices, LZAGF is priced at $629.71, while RGDXQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, LZAGF is less volatile compared to RGDXQ. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check RGDXQ's competition here
LZAGF vs DMTKQ Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, DMTKQ has a market cap of 3.5K. Regarding current trading prices, LZAGF is priced at $629.71, while DMTKQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas DMTKQ's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to DMTKQ's ROE of -1.06%. Regarding short-term risk, LZAGF is more volatile compared to DMTKQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check DMTKQ's competition here
LZAGF vs MEDVF Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, MEDVF has a market cap of 2.7K. Regarding current trading prices, LZAGF is priced at $629.71, while MEDVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas MEDVF's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to MEDVF's ROE of +2.13%. Regarding short-term risk, LZAGF is more volatile compared to MEDVF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check MEDVF's competition here
LZAGF vs IHTI Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, IHTI has a market cap of 1.6K. Regarding current trading prices, LZAGF is priced at $629.71, while IHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas IHTI's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, LZAGF is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check IHTI's competition here
LZAGF vs GWHP Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, GWHP has a market cap of 1.3K. Regarding current trading prices, LZAGF is priced at $629.71, while GWHP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas GWHP's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to GWHP's ROE of +6.19%. Regarding short-term risk, LZAGF is less volatile compared to GWHP. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check GWHP's competition here
LZAGF vs ROSGQ Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, ROSGQ has a market cap of 593. Regarding current trading prices, LZAGF is priced at $629.71, while ROSGQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to ROSGQ's ROE of -1.35%. Regarding short-term risk, LZAGF is more volatile compared to ROSGQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check ROSGQ's competition here
LZAGF vs BIOCQ Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, BIOCQ has a market cap of 263. Regarding current trading prices, LZAGF is priced at $629.71, while BIOCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas BIOCQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, LZAGF is more volatile compared to BIOCQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BIOCQ's competition here
LZAGF vs HTGMQ Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, HTGMQ has a market cap of 221. Regarding current trading prices, LZAGF is priced at $629.71, while HTGMQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, LZAGF is more volatile compared to HTGMQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check HTGMQ's competition here
LZAGF vs OPGX Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, OPGX has a market cap of 17. Regarding current trading prices, LZAGF is priced at $629.71, while OPGX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas OPGX's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, LZAGF is less volatile compared to OPGX. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check OPGX's competition here
LZAGF vs BGNX Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, BGNX has a market cap of 0. Regarding current trading prices, LZAGF is priced at $629.71, while BGNX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas BGNX's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to BGNX's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to BGNX. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BGNX's competition here
LZAGF vs AGHC Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, AGHC has a market cap of 0. Regarding current trading prices, LZAGF is priced at $629.71, while AGHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas AGHC's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, LZAGF is more volatile compared to AGHC. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check AGHC's competition here
LZAGF vs EPGNY Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, EPGNY has a market cap of 0. Regarding current trading prices, LZAGF is priced at $629.71, while EPGNY trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, LZAGF's ROE is +0.10%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, LZAGF is more volatile compared to EPGNY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check EPGNY's competition here
LZAGF vs MRPS Comparison May 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 43.2B. In comparison, MRPS has a market cap of 0. Regarding current trading prices, LZAGF is priced at $629.71, while MRPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 37.47, whereas MRPS's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to MRPS's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to MRPS. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check MRPS's competition here